Hamza Almusabeh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Hamza Almusabeh has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
Kanwarpreet Tandon
Section of Gastroenterology and Hepatology, Department of Medicine, West Virginia University School of Medicine
3 shared publicationsKhaled Elfert
Section of Gastroenterology and Hepatology, Department of Medicine, West Virginia University School of Medicine
3 shared publications- Ayowumi Adekolu
Division of Gastroenterology and Hepatology, West Virginia University, Morgantown, WV
2 shared publications Jennifer Hadam-Veverka
Section of Gastroenterology and Hepatology, Department of Medicine, West Virginia University School of Medicine
2 shared publicationsKatherine Shepherd
Department of Medicine, West Virginia University School of Medicine
2 shared publicationsOlanrewaju Adeniran
Department of Medicine, West Virginia University School of Medicine
2 shared publications
Latest Publications
- Open Access
- 1 September 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (9)
Recurrent Jejunal Melanoma Presenting as Obscure Gastrointestinal Bleeding: A Diagnostic Challenge
Melanoma commonly metastasizes to the gastrointestinal tract but is often asymptomatic. Symptomatic small intestinal metastatic melanoma presenting with overt gastrointestinal bleeding is uncommon and may be difficult to diagnose when the initial radiographic and endoscopic workup is unrevealing. We report a 47-year-old patient with prior stage III cutaneous melanoma status post wide local excision and sentinel lymph node biopsy, who declined adjuvant immunotherapy and surveillance, presenting with acute blood loss anemia occurring 3 years after definitive treatment. After nondiagnostic radiographic evaluation, esophagogastroduodenoscopy, colonoscopy, and push enteroscopy, anterograde double-balloon enteroscopy revealed an actively bleeding ulcerated midjejunal mass, later measuring 6 cm on surgical pathology, with pathology confirming the diagnosis of metastatic melanoma.
- 1 September 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (9)
Open AccessRecurrent Jejunal Melanoma Presenting as Obscure Gastrointestinal Bleeding: A Diagnostic Challenge
Melanoma commonly metastasizes to the gastrointestinal tract but is often asymptomatic. Symptomatic small intestinal metastatic melanoma presenting with overt gastrointestinal bleeding is uncommon and may be difficult to diagnose when the initial radiographic and endoscopic workup is unrevealing. We report a 47-year-old patient with prior stage III cutaneous melanoma status post wide local excision and sentinel lymph node biopsy, who declined adjuvant immunotherapy and surveillance, presenting with acute blood loss anemia occurring 3 years after definitive treatment. After nondiagnostic radiographic evaluation, esophagogastroduodenoscopy, colonoscopy, and push enteroscopy, anterograde double-balloon enteroscopy revealed an actively bleeding ulcerated midjejunal mass, later measuring 6 cm on surgical pathology, with pathology confirming the diagnosis of metastatic melanoma.
- Open Access
- 1 May 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (5)
Metastatic Crohn Disease Manifesting as Granulomatous Cheilitis in a Patient With Well-Controlled Crohn Disease
Crohn disease (CD) can affect any organ system outside the gastrointestinal tract, and these conditions are classified as extraintestinal manifestations and include arthritis, uveitis, and cutaneous manifestations. Cutaneous involvement includes erythema nodosum, pyoderma gangrenosum, and metastatic CD. The latter can be defined as a granulomatous skin lesion that is noncontiguous to the intestinal disease. In this article, we report a rare case of a 48-year-old woman with CD in endoscopic and clinical remission with chronic persistent orofacial granulomatosis of the lip secondary to CD, despite the absence of active intestinal disease and describe its management.
- 1 May 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (5)
Open AccessMetastatic Crohn Disease Manifesting as Granulomatous Cheilitis in a Patient With Well-Controlled Crohn Disease
Crohn disease (CD) can affect any organ system outside the gastrointestinal tract, and these conditions are classified as extraintestinal manifestations and include arthritis, uveitis, and cutaneous manifestations. Cutaneous involvement includes erythema nodosum, pyoderma gangrenosum, and metastatic CD. The latter can be defined as a granulomatous skin lesion that is noncontiguous to the intestinal disease. In this article, we report a rare case of a 48-year-old woman with CD in endoscopic and clinical remission with chronic persistent orofacial granulomatosis of the lip secondary to CD, despite the absence of active intestinal disease and describe its management.
- 13 April 2026
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 39 (4) , 563-567
Comparing the risk of heart failure in patients with inflammatory bowel disease treated with infliximab versus adalimumab: a retrospective cohort study using a national database
Anti–tumor necrosis factor (TNF) agents are widely used for inflammatory bowel disease and have well-documented heart failure risk, but comparative cardiac safety remains uncertain. We conducted a retrospective cohort study using the TriNetX US national database. Adults with Crohn’s disease or ulcerative colitis initiating infliximab or adalimumab were included. Patients with prior heart failure were excluded. The primary outcome was heart failure occurring ≥ 6 months after anti-TNF initiation. Propensity score matching was performed to balance baseline covariates. Before matching, 25,582 patients received infliximab and 24,301 received adalimumab. After matching, 21,554 remained in each group. Median follow-up was ≈ 3.65 years (infliximab) and ≈ 3.91 years (adalimumab). Heart failure occurred in 466 (2.21%) infliximab patients vs 383 (1.81%) adalimumab patients (risk ratio, 1.22; 95% confidence interval [CI] 1.068–1.395; P = 0.003). In an exploratory Cox model, infliximab was associated with a higher heart failure hazard, 1.179 (95% CI 1.029–1.35), and a significant Kaplan-Meier curve by log-rank test (P = 0.02). In this national database analysis of patients with inflammatory bowel disease, infliximab was associated with a higher observed risk of incident heart failure compared with adalimumab.
- 13 April 2026
- Published by Taylor & Francis in Baylor University Medical Center Proceedings
- Vol. 39 (4) , 563-567
Comparing the risk of heart failure in patients with inflammatory bowel disease treated with infliximab versus adalimumab: a retrospective cohort study using a national database
Anti–tumor necrosis factor (TNF) agents are widely used for inflammatory bowel disease and have well-documented heart failure risk, but comparative cardiac safety remains uncertain. We conducted a retrospective cohort study using the TriNetX US national database. Adults with Crohn’s disease or ulcerative colitis initiating infliximab or adalimumab were included. Patients with prior heart failure were excluded. The primary outcome was heart failure occurring ≥ 6 months after anti-TNF initiation. Propensity score matching was performed to balance baseline covariates. Before matching, 25,582 patients received infliximab and 24,301 received adalimumab. After matching, 21,554 remained in each group. Median follow-up was ≈ 3.65 years (infliximab) and ≈ 3.91 years (adalimumab). Heart failure occurred in 466 (2.21%) infliximab patients vs 383 (1.81%) adalimumab patients (risk ratio, 1.22; 95% confidence interval [CI] 1.068–1.395; P = 0.003). In an exploratory Cox model, infliximab was associated with a higher heart failure hazard, 1.179 (95% CI 1.029–1.35), and a significant Kaplan-Meier curve by log-rank test (P = 0.02). In this national database analysis of patients with inflammatory bowel disease, infliximab was associated with a higher observed risk of incident heart failure compared with adalimumab.
- 30 March 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (8) , 1-3
Inadvertent Ampullary Closure Following Duodenal Ulcer Treatment with an Over-the-Scope Clip
During the initial EGD, urgent side-viewing EGD revealed the OTSC adjacent to the ampulla. The clip was removed using ice-cold water irrigation, an OTSC DC cutter, and rat-toothed forceps, resulting in immediate biliary drainage.
- 30 March 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (8) , 1-3
Inadvertent Ampullary Closure Following Duodenal Ulcer Treatment with an Over-the-Scope Clip
During the initial EGD, urgent side-viewing EGD revealed the OTSC adjacent to the ampulla. The clip was removed using ice-cold water irrigation, an OTSC DC cutter, and rat-toothed forceps, resulting in immediate biliary drainage.
- 25 March 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (8) , 3594-3601
Risk of Autoimmune Hepatitis Among Patients with Inflammatory Bowel Disease Treated with Infliximab: A Retrospective Cohort Study Using a National Database
Infliximab and adalimumab are widely used anti-tumor necrosis factor agents for inflammatory bowel disease, both with reported cases of drug-induced autoimmune hepatitis. However, comparative data on the risk of autoimmune hepatitis with infliximab versus adalimumab are limited. We aimed to compare the risk of autoimmune hepatitis among patients with inflammatory bowel disease treated with infliximab versus adalimumab. We conducted a retrospective active-comparator, new-user cohort study using the TriNetX US collaborative network. Adults with Crohn's disease or ulcerative colitis who initiated infliximab or adalimumab were included. Patients with prior autoimmune hepatitis, prior exposure to the alternate anti-tumor necrosis factor agent, selected autoimmune comorbidities, or other biologic exposure were excluded. The primary outcome was new autoimmune hepatitis occurring at least 3 months after treatment initiation. Propensity score matching was performed to balance baseline covariates. A sensitivity analysis was also conducted including autoimmune comorbidities in the matching model. After propensity score matching, 15,298 patients remained in each group. Autoimmune hepatitis occurred in 33 patients (0.216%) treated with infliximab and 13 patients (0.085%) treated with adalimumab. Infliximab was associated with a higher risk of autoimmune hepatitis (risk ratio 2.53; 95% confidence interval (CI) 1.336-4.818; P = 0.0032). Time-to-event analysis showed similar findings (hazard ratio 2.602; 95% CI 1.369-4.945). In the sensitivity analysis, infliximab remained associated with a higher risk of autoimmune hepatitis. In this large national cohort of patients with inflammatory bowel disease, infliximab was associated with a higher observed risk of autoimmune hepatitis compared with adalimumab.
- 25 March 2026
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 71 (8) , 3594-3601
Risk of Autoimmune Hepatitis Among Patients with Inflammatory Bowel Disease Treated with Infliximab: A Retrospective Cohort Study Using a National Database
Infliximab and adalimumab are widely used anti-tumor necrosis factor agents for inflammatory bowel disease, both with reported cases of drug-induced autoimmune hepatitis. However, comparative data on the risk of autoimmune hepatitis with infliximab versus adalimumab are limited. We aimed to compare the risk of autoimmune hepatitis among patients with inflammatory bowel disease treated with infliximab versus adalimumab. We conducted a retrospective active-comparator, new-user cohort study using the TriNetX US collaborative network. Adults with Crohn's disease or ulcerative colitis who initiated infliximab or adalimumab were included. Patients with prior autoimmune hepatitis, prior exposure to the alternate anti-tumor necrosis factor agent, selected autoimmune comorbidities, or other biologic exposure were excluded. The primary outcome was new autoimmune hepatitis occurring at least 3 months after treatment initiation. Propensity score matching was performed to balance baseline covariates. A sensitivity analysis was also conducted including autoimmune comorbidities in the matching model. After propensity score matching, 15,298 patients remained in each group. Autoimmune hepatitis occurred in 33 patients (0.216%) treated with infliximab and 13 patients (0.085%) treated with adalimumab. Infliximab was associated with a higher risk of autoimmune hepatitis (risk ratio 2.53; 95% confidence interval (CI) 1.336-4.818; P = 0.0032). Time-to-event analysis showed similar findings (hazard ratio 2.602; 95% CI 1.369-4.945). In the sensitivity analysis, infliximab remained associated with a higher risk of autoimmune hepatitis. In this large national cohort of patients with inflammatory bowel disease, infliximab was associated with a higher observed risk of autoimmune hepatitis compared with adalimumab.
- Open Access
- 1 December 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (12)
When the Rectal Protection Barrier Causes Complications: Recognizing Spacer-Induced Rectal Fistula
- 1 December 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (12)
Open AccessWhen the Rectal Protection Barrier Causes Complications: Recognizing Spacer-Induced Rectal Fistula
- Open Access
- 1 November 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (11) , e01896
Successful Endoscopic Ultrasound-Guided Radiofrequency Ablation for Symptomatic Insulinoma in a High-Risk Elderly Patient
We describe a case of symptomatic pancreatic insulinoma in an 80-year-old man with multiple comorbidities. The patient underwent endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA). After biochemical suspicion of endogenous hyperinsulinemic hypoglycemia, imaging revealed a 9 × 18 mm pancreatic body mass confirmed as a World Health Organization grade 1 insulinoma on histopathology. Given the high surgical risk, we performed a EUS-RFA with 13 sequential ablations. Blood glucose normalized within 48 hours postprocedure. The lesion reduced significantly in size, with no recurrence of hypoglycemia observed up to an 18-month follow-up. EUS-RFA offers a safe and effective alternative to surgery for insulinoma in medically vulnerable patients.
- 1 November 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (11) , e01896
Open AccessSuccessful Endoscopic Ultrasound-Guided Radiofrequency Ablation for Symptomatic Insulinoma in a High-Risk Elderly Patient
We describe a case of symptomatic pancreatic insulinoma in an 80-year-old man with multiple comorbidities. The patient underwent endoscopic ultrasound-guided radiofrequency ablation (EUS-RFA). After biochemical suspicion of endogenous hyperinsulinemic hypoglycemia, imaging revealed a 9 × 18 mm pancreatic body mass confirmed as a World Health Organization grade 1 insulinoma on histopathology. Given the high surgical risk, we performed a EUS-RFA with 13 sequential ablations. Blood glucose normalized within 48 hours postprocedure. The lesion reduced significantly in size, with no recurrence of hypoglycemia observed up to an 18-month follow-up. EUS-RFA offers a safe and effective alternative to surgery for insulinoma in medically vulnerable patients.
- Open Access
Predictors of Recurrent Acute Chest Syndrome in Pediatric Sickle Cell Disease: A Retrospective Case-Control Study
Acute chest syndrome (ACS) is a common cause of death in sickle cell disease (SCD) patients. Multiple studies investigated the risk factors of developing ACS; however, predictors of recurrent ACS episodes have not been thoroughly investigated. We aim to examine the clinical and laboratory predictors of recurrent ACS in pediatric patients with SCD. A retrospective case-control study included pediatric patients with SCD (˂14 years) admitted with ACS or developed ACS during admission for another indication. Patients were classified into recurrent ACS episodes (≥2 episodes) and a single ACS episode groups. Ninety-one ACS episodes (42 patients) were included, with a mean age at diagnosis of 7.18 ± 3.38 years. Twenty-two (52.4%) patients were male, and twenty-five (59.5%) patients had recurrent ACS. Younger age at first ACS was significantly associated with recurrence (p = 0.003), with an optimal cutoff at 7.5 years (area under the receiver operating characteristic curve [AUROC] = 0.833; p < 0.001). Higher SCD-related hospitalizations were significantly associated with recurrence (p = 0.038). Higher mean values of baseline white blood count (WBC) (p = 0.009), mean corpuscular volume (MCV) (p = 0.011), and reticulocyte (p = 0.036) were significantly associated with recurrence. Contrarily, lower baseline hematocrit values (p = 0.016) were significantly associated with recurrence. The ACS frequencies were significantly lower after hydroxyurea (p = 0.021). The odds of ACS recurrence increased with a positive C-reactive protein (CRP) at admission (p = 0.006). In conclusion, several baseline and admission laboratory data showed significant associations with recurrence. Hydroxyurea therapy demonstrated reduced ACS episodes.
Open AccessPredictors of Recurrent Acute Chest Syndrome in Pediatric Sickle Cell Disease: A Retrospective Case-Control Study
Acute chest syndrome (ACS) is a common cause of death in sickle cell disease (SCD) patients. Multiple studies investigated the risk factors of developing ACS; however, predictors of recurrent ACS episodes have not been thoroughly investigated. We aim to examine the clinical and laboratory predictors of recurrent ACS in pediatric patients with SCD. A retrospective case-control study included pediatric patients with SCD (˂14 years) admitted with ACS or developed ACS during admission for another indication. Patients were classified into recurrent ACS episodes (≥2 episodes) and a single ACS episode groups. Ninety-one ACS episodes (42 patients) were included, with a mean age at diagnosis of 7.18 ± 3.38 years. Twenty-two (52.4%) patients were male, and twenty-five (59.5%) patients had recurrent ACS. Younger age at first ACS was significantly associated with recurrence (p = 0.003), with an optimal cutoff at 7.5 years (area under the receiver operating characteristic curve [AUROC] = 0.833; p < 0.001). Higher SCD-related hospitalizations were significantly associated with recurrence (p = 0.038). Higher mean values of baseline white blood count (WBC) (p = 0.009), mean corpuscular volume (MCV) (p = 0.011), and reticulocyte (p = 0.036) were significantly associated with recurrence. Contrarily, lower baseline hematocrit values (p = 0.016) were significantly associated with recurrence. The ACS frequencies were significantly lower after hydroxyurea (p = 0.021). The odds of ACS recurrence increased with a positive C-reactive protein (CRP) at admission (p = 0.006). In conclusion, several baseline and admission laboratory data showed significant associations with recurrence. Hydroxyurea therapy demonstrated reduced ACS episodes.